Understanding GLP-1 Medications GLP-1 is a natural hormone that regulates appetite by signalling fullness to the brain, slowing gastric emptying, enhancing insulin secretion, and reducing glucagon levels
Physiologically, it can bind to GLP-1 receptor on pancreatic beta cells through endocrine, activate adenylate cyclase, increase intracellular cAMP levels, promote glycolysis and ATP production, and enhance glucose-stimulated insulin secretion
Food is Medicine 101 The Food is Medicine 101 continuing education course through University College aims to educate health professionals on the critical link between nutrition and health and its application to the healthcare setting
Medications licensed for type 2 diabetes include: Exenatide (Byetta, Bydureon): Available as twice-daily injections or once-weekly extended-release formulation Liraglutide (Victoza): Administered as a once-daily subcutaneous injection at doses up to 1.8 mg for diabetes Dulaglutide (Trulicity): Once-weekly injection with pre-filled pen devices Semaglutide (Ozempic): Once-weekly injection for diabetes management Oral semaglutide (Rybelsus): The first oral GLP-1 agonist, taken daily For weight management specifically, two formulations have received UK marketing authorisation: Liraglutide 3.0 mg (Saxenda): Licensed for weight management in adults with a BMI 30 kg/m, or 27 kg/m with weight-related comorbidities Semaglutide 2.4 mg (Wegovy): Once-weekly injection approved for chronic weight management under similar BMI criteria It is crucial to understand that whilst these medications demonstrate efficacy in promoting weight loss, they are not specifically indicated for leptin resistance
But Foundayo works differently at a structural level
